NIH Research
Researchers discover single-cell brain activity that underlies human speech
With neuronal data, AI models predicted grammar, meaning, and context of spoken sentences.
Latest medical news · page 98
The latest headlines across every section, pulled from official and open-access sources.
Fierce Biotech
‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game
John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of the antibody-drug conjugate specialist’s new five-year plan, which aims to lay the groundwork for Daiichi to become a global top 5 oncology company by 2035.
Fierce Biotech
F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test
F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.
Fierce Biotech
Biogen inks $1B RayThera buyout to bag preclinical immunology assets
Biogen has struck a backloaded, $1 billion deal to buy RayThera, snagging a pipeline of anti-inflammatory drug candidates led by a prospect on the cusp of clinical development.
Fierce Biotech
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
Innoviva has revealed the next steps for Langer Lab assets it rescued from Lyndra Therapeutics’ collapse, launching Nortiva Bio to develop long-acting oral medicines and pursue drug development alliances.
Fierce Biotech
UPDATED: Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3
Kardigan’s IPO haul has come in 14% above expectations, grossing $400 million after the cardiovascular disease biotech upsized the offering and hit the top end of its target range.
Fierce Biotech
Novocure device fails to improve brain cancer patients’ survival in phase 3 test
Novocure’s tumor-treating electric fields device missed its primary endpoint in a late-stage glioblastoma trial.
Fierce Biotech
cAMPfield harvests $180M series A to advance oral IBD drug licensed from Newsoara
In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.
Fierce Biotech
Moderna’s flu candidate sails through FDA advisory committee in unanimous votes
As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza vaccination market.
Fierce Biotech
Redefining what success looks like in PSC: The evolution of clinical trial endpoints
As understanding of rare cholestatic liver diseases has evolved, endpoint science and patient engagement may help shape future PSC research.
Fierce Biotech
How data-driven diagnostic lab services drive precise clinical trial enrollment
Drug commercialization depends on reaching the right physicians at the right moment.
Fierce Biotech
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development
Explore how FDA Breakthrough Therapy and RMAT designations can create opportunities for oncology programs when backed by the right development strategy.
Fierce Biotech
Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm
Insilico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune disorders in a deal that could be worth more than $2.5 billion.
Fierce Biotech
A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress tests.
Fierce Biotech
Sanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum
Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring Paulo Fontoura, M.D., Ph.D., to replace Houman Ashrafian, Ph.D., as the head of the company’s stuttering R&D group.
Fierce Biotech
Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets
Bionyra is emerging from stealth with an oversubscribed Series A round of $165 million co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in the round after the company received seed financing from Sofinnova Partners.
Fierce Biotech
Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
From its headquarters in the heart of New York City, Definium Therapeutics has dropped topline phase 3 data for its psychedelic answer to depression that is almost certain to keep the field’s hype train rolling.
Fierce Biotech
For biopharma manufacturing at speed and scale, the future is flexible
Biopharma development has long trended toward specialized and personalized therapies such as cell and gene therapies, antibody-drug conjugates, and monoclonal antibodies (mAbs), among others.
Fierce Biotech
AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect
AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.
Fierce Biotech
Sanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease
French biopharma Sanofi inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD) that will be distributed to select healthcare systems and low-income community care clinics.
Fierce Biotech
Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis
Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.
Fierce Biotech
In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy
In another sign that the FDA is easing its stance toward rare disease drug candidates under new leadership, the agency will reconsider Regenxbio’s gene therapy for an ultra-rare childhood disease, a reversal coming just about four months after a rejection.
Fierce Biotech
Rethinking controls: The rise of VCGs in drug development
Virtual control groups are redefining study design—cutting animal use while advancing rigor and regulatory momentum.
Fierce Biotech
Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months
As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of a series of efforts to regain ground on China’s surging early-stage clinical development capabilities.